Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.
The most recent EPS for Dyne Therapeutics, Inc is $, expectations of $-0.78.
How did Dyne Therapeutics, Inc DYN's revenue perform in the last quarter?
Dyne Therapeutics, Inc revenue for the last quarter is $
What is the revenue estimate for Dyne Therapeutics, Inc?
According to 11 of Wall street analyst, the revenue estimate of Dyne Therapeutics, Inc range from $0.0 to $0.0
What's the earning quality score for Dyne Therapeutics, Inc?
Dyne Therapeutics, Inc has a earning quality score of B+/45.721836. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Dyne Therapeutics, Inc report earnings?
Dyne Therapeutics, Inc next earnings report is expected in 2026-08-04
What are Dyne Therapeutics, Inc's expected earnings?
Dyne Therapeutics, Inc expected earnings is $0.0, according to wall-street analysts.
Did Dyne Therapeutics, Inc beat earnings expectations?
Dyne Therapeutics, Inc recent earnings of $ expectations.